Keywords: AstraZeneca, Crestor, Australia, Patent invalidation, Cholesterol lowerer

AstraZeneca's Crestor patent rule invalid in Australia

Article | 05 March 2013

Print This

Anglo-Swedish drug major AstraZeneca (LSE: AZN) revealed this morning that the Federal Court of Australia has found three patents protecting ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in